The Role of Plasma Calprotectin in Non-infectious Uveitis

References

• de Smet MD, Taylor SRJ, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, LeHoang P, Lightman S. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452–70. doi:10.1016/j.preteyeres.2011.06.005.
   PubMed Web of Science ®Google Scholar
• Adán-Civera AM, Benítez-del-Castillo JM, Blanco-Alonso R, Pato-Cour E, Sellas-Fernández A, Bañares-Cañizares A. Carga y costes directos de la uveítis no infecciosa en España. Reumatol Clín. 2016;12(4):196–200. doi:10.1016/j.reuma.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Groen-Hakan F, Eurelings L, van Laar J, Rothova A. Relevance of erythrocyte sedimentation rate and C-reactive protein in patients with active uveitis. Graefes Arch Clin Exp Ophthalmol. 2019;257(1):175–80. doi:10.1007/s00417-018-4174-7.
   PubMed Web of Science ®Google Scholar
• Invernizzi A, Marchi S, Aldigeri R, Mastrofilippo V, Viscogliosi F, Soldani A, Garoli E, Viola F, Fontana L, McCluskey P, et al. Objective quantification of anterior chamber inflammation. Ophthalmology. 2017;124(11):1670–77. doi:10.1016/j.ophtha.2017.05.013.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Keane PA, Sim DA, Llorens V, Tufail A, Sadda SR, Dick AD, Lee RW, Pavesio C, Denniston AK, et al. Evaluation of objective vitritis grading method using optical coherence tomography: influence of phakic status and previous vitrectomy. Am J Ophthalmol. 2016;161:172–180.e4. doi:10.1016/j.ajo.2015.10.009.
   PubMed Web of Science ®Google Scholar
• Denniston AK, Keane PA, Srivastava SK. Biomarkers and surrogate endpoints in uveitis: the impact of quantitative imaging. Invest Opthalmology Vis Sci. 2017;58(6):BIO131–BIO140. doi:10.1167/iovs.17-21788.
   PubMed Web of Science ®Google Scholar
• Pato E, Martin-Martinez MA, Castelló A, Méndez-Fernandez R, Muñoz-Fernández S, Cordero-Coma M, Martínez-Costa L, Valls E, Reyes M, Francisco F, et al. Development of an activity disease score in patients with uveitis (UVEDAI). Rheumatol Int. 2017;37(4):647–56. doi:10.1007/s00296-016-3593-1.
   PubMed Web of Science ®Google Scholar
• Ometto F, Friso L, Astorri D, Botsios C, Raffeiner B, Punzi L, Doria A. Calprotectin in rheumatic diseases. Exp Biol Med. 2017;242(8):859–73. doi:10.1177/1535370216681551.
   PubMed Web of Science ®Google Scholar
• Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MAD, Nacken W, Foell D, van der Poll T, Sorg C, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13(9):1042–49. doi:10.1038/nm1638.
   PubMed Web of Science ®Google Scholar
• Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H, Chazin WJ, Nakatani Y, Yui S, Makino H. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther. 2006;8(3):R69. doi:10.1186/ar1939.
   PubMed Web of Science ®Google Scholar
• Sander J, Fagerhol MK, Bakken JS, Dale I. Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein. Scand J Clin Lab Invest. 1984;44(4):357–62. doi:10.3109/00365518409083820.
   PubMed Web of Science ®Google Scholar
• Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42(5):760–70. doi:10.3899/jrheum.140628.
   PubMed Web of Science ®Google Scholar
• Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, Su Y. Serum calprotectin—a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol. 2016;35(1):73–79. doi:10.1007/s10067-015-3108-6.
   PubMed Web of Science ®Google Scholar
• Oktayoglu P, Mete N, Caglayan M, Bozkurt M, Bozan T, Em S, Nas K. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet’s disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2015;75(2):106–12. doi:10.3109/00365513.2014.984319.
   PubMed Web of Science ®Google Scholar
• Nordal H, Brun J, Halse A-K, Madland T, Fagerhol M, Jonsson R. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome. Scand J Rheumatol. 2014;43(1):76–78. doi:10.3109/03009742.2013.848930.
   PubMed Web of Science ®Google Scholar
• Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CGM, Langford CA, Monach PA, Seo P, Spiera R, et al. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis: S100A8/A9 AND RELAPSE IN PR3-ANCA-ASSOCIATED VASCULITIS. Arthritis Rheumatol. 2017;69(1):185–93. doi:10.1002/art.39814.
   PubMed Web of Science ®Google Scholar
• Aochi S, Tsuji K, Sakaguchi M, Huh N, Tsuda T, Yamanishi K, Komine M, Iwatsuki K. Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. J Am Acad Dermatol. 2011;64(5):879–87. doi:10.1016/j.jaad.2010.02.049.
   PubMed Web of Science ®Google Scholar
• Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, Roth J. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(3):883–91. doi:10.1002/art.24349.
   PubMed Web of Science ®Google Scholar
• Haga H-J, Brun JG, Berner Berntzen H, Cervera R, Khamashta M, Hughes GRV. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus. 1993;2(1):47–50. doi:10.1177/096120339300200108.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Kvien TK, Glennås A, Melby K. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol. 1995;13:59–64.
   PubMed Web of Science ®Google Scholar
• Huang J, Yin Z, Song G, Cui S, Jiang J, Zhang L. Discriminating value of calprotectin in disease activity and progression of nonradiographic axial spondyloarthritis and ankylosing spondylitis. Dis Markers. 2017;2017:7574147. doi:10.1155/2017/7574147.
   PubMed Web of Science ®Google Scholar
• Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014;62(6):880–84. doi:10.1097/JIM.0000000000000095.
   PubMed Web of Science ®Google Scholar
• Shabani F, Farasat A, Mahdavi M, Gheibi N. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res. 2018;67(10):801–12. doi:10.1007/s00011-018-1173-4.
   PubMed Web of Science ®Google Scholar
• Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros. 2010;9(3):193–98. doi:10.1016/j.jcf.2010.01.005.
   PubMed Web of Science ®Google Scholar
• Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, Foell D, Gerke V, Manitz MP, Nacken W, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104(13):4260–68. doi:10.1182/blood-2004-02-0446.
   PubMed Web of Science ®Google Scholar
• Turina MC, Yeremenko N, Paramarta JE, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16(4):413. doi:10.1186/s13075-014-0413-4.
   PubMed Web of Science ®Google Scholar
• Hu H, Du F, Zhang S, Zhang W. Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment. Mod Rheumatol. 2019;29(5):836–42. doi:10.1080/14397595.2018.1519103.
   PubMed Web of Science ®Google Scholar
• Nordal HH, Brokstad KA, Solheim M, Halse A-K, Kvien TK, Hammer HB. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):3. doi:10.1186/s13075-016-1201-0.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Hernández MV, Ruiz-Esquide V, Cabrera-Villalba SR, Ramirez J, Cuervo A, Pascal M, Yagüe J, Cañete JD, Sanmartí R. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors: calprotectin, CRP, and ESR in RA patients receiving TNFi. Arthritis Care Res. 2016;68(7):899–906. doi:10.1002/acr.22795.
   Web of Science ®Google Scholar
• Chen Y-S, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11(2):R39. doi:10.1186/ar2645.
   PubMed Web of Science ®Google Scholar
• Kang KY, Woo J-W, Park S-H. S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. Korean J Intern Med. 2014;29(1):12–19. doi:10.3904/kjim.2014.29.1.12.
   PubMed Web of Science ®Google Scholar
• Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M, Baeten D, Poddubnyy D. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014;73(9):1746–48. doi:10.1136/annrheumdis-2014-205506.
   PubMed Web of Science ®Google Scholar
• Olson JA, Forrester M, Clohessy PA, Golden BE, Herriot R, Forrester JV. Calprotectin is raised in endogenous posterior uveitis. Ocul Immunol Inflamm. 1996;4(2):91–98. doi:10.3109/09273949609079638.
   PubMed Web of Science ®Google Scholar
• Walscheid K, Heiligenhaus A, Holzinger D, Roth J, Heinz C, Tappeiner C, Kasper M, Foell D. Elevated S100A8/A9 and S100A12 serum levels reflect intraocular inflammation in juvenile idiopathic arthritis-associated uveitis: results from a pilot study. Invest Opthalmology Vis Sci. 2015;56(13):7653–60. doi:10.1167/iovs.15-17066.
   PubMed Web of Science ®Google Scholar
• Song G, Huang J, Deng Y, Liang Z, Lin Y. The expression of calprotectin and factors in TLR4/NF-κB/MyD88 pathway in patients with idiopathic acute anterior uveitis. Ocul Immunol Inflamm. 2019;27(7):1144–48. doi:10.1080/09273948.2018.1485956.
   PubMed Web of Science ®Google Scholar
• Wang Y-Q, Dai X-D, Ran Y, Cao Y, Lan C-L, Guan J-T, Liu C, Yang F-M, Gan Y-J, Liu B-J, et al. Circulating S100A8/A9 levels reflect intraocular inflammation in uveitis patients. Ocul Immunol Inflamm. 2020;28(1):133–41. doi:10.1080/09273948.2018.1538461.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16.
   PubMed Web of Science ®Google Scholar
• Pedersen L, Nybo M, Poulsen MK, Henriksen JE, Dahl J, Rasmussen LM. Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC Cardiovasc Disord. 2014;14(1):196. doi:10.1186/1471-2261-14-196.
   PubMed Web of Science ®Google Scholar
• Yun J, Xiao T, Zhou L, Beuerman RW, Li J, Zhao Y, Hadayer A, Zhang X, Sun D, Kaplan HJ, et al. Local S100A8 levels correlate with recurrence of experimental autoimmune uveitis and promote pathogenic T cell activity. Invest Opthalmology Vis Sci. 2018;59(3):1332–42. doi:10.1167/iovs.17-23127.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol. 2008;146(6):813–818.e1. doi:10.1016/j.ajo.2008.06.004.
   PubMed Web of Science ®Google Scholar
• Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol. 1994;21:733–38.
   PubMed Web of Science ®Google Scholar
• Brun JG, Madland TM, Gran JT, Myklebust G. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand J Rheumatol. 2005;34(2):125–28. doi:10.1080/03009740410009931.
   PubMed Web of Science ®Google Scholar
• Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d’Elia H. Calprotectin in ankylosing spondylitis – frequently elevated in feces, but normal in serum. Scand J Gastroenterol. 2012;47(4):435–44. doi:10.3109/00365521.2011.648953.
   PubMed Web of Science ®Google Scholar